HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial
…, M Hegde, K Bielamowicz, M Kalra, D Landi… - JAMA …, 2017 - jamanetwork.com
Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are
limited. Objective To determine whether the systemic administration of HER2-specific …
limited. Objective To determine whether the systemic administration of HER2-specific …
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence
after treatment with CAR T cells that are redirected to single tumor antigens. Given the …
after treatment with CAR T cells that are redirected to single tumor antigens. Given the …
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning
…, TA Driscoll, J Kurtzberg, DB Landi… - Blood, The Journal …, 2013 - ashpublications.org
We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a
myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months …
myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months …
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
LB Kilburn, DA Khuong-Quang, JR Hansford, D Landi… - Nature medicine, 2024 - nature.com
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …
glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …
TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer
…, VS Salsman, HZ Oo, K Bielamowicz, D Landi… - Cancer research, 2018 - AACR
Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In
this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a …
this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a …
Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.
…, A Ashoori, O Diouf, C Gerken, D Landi… - … for immunotherapy of …, 2015 - Springer
Glioblastoma (GBM) remains incurable with current standard-of-care therapies. Adoptive T
cell transfer holds the promise to improve outcomes for GBM patients. We report on the …
cell transfer holds the promise to improve outcomes for GBM patients. We report on the …
[HTML][HTML] Current medulloblastoma subgroup specific clinical trials
EM Thompson, D Ashley, D Landi - Translational pediatrics, 2020 - ncbi.nlm.nih.gov
Medulloblastoma is a heterogeneous disease with at least four distinct molecular subgroups:
wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4. Recently there has been …
wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4. Recently there has been …
Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial
EM Thompson, D Landi, MC Brown… - The Lancet Child & …, 2023 - thelancet.com
Background Outcomes of recurrent paediatric high-grade glioma are poor, with a median
overall survival of less than 6 months. Viral immunotherapy, such as the polio–rhinovirus …
overall survival of less than 6 months. Viral immunotherapy, such as the polio–rhinovirus …
Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015 …
…, C Neff, JB Iorgulescu, DB Landi… - Neuro-Oncology …, 2024 - academic.oup.com
… Daniel B Landi , Daniel B Landi … Mackenzie Price, Katherine Ryan, Madison L Shoaf,
Corey Neff, J Bryan Iorgulescu, Daniel B Landi, Gino Cioffi, Kristin A Waite, Carol Kruchko, Jill S …
Corey Neff, J Bryan Iorgulescu, Daniel B Landi, Gino Cioffi, Kristin A Waite, Carol Kruchko, Jill S …
A pilot study omitting radiation in the treatment of children with newly diagnosed Wnt-activated medulloblastoma
…, D Aguilera, RC Castellino, SL Stapleton, D Landi… - Clinical Cancer …, 2023 - AACR
Purpose: Treatment of wingless (WNT)-activated medulloblastoma (WNT+MB) with surgery,
irradiation (XRT), and chemotherapy results in excellent outcomes. We studied the efficacy …
irradiation (XRT), and chemotherapy results in excellent outcomes. We studied the efficacy …